EMA Authorised: Diacomit (stiripentol) — Biocodex

View source ↗

Summary

The EMA authorised Diacomit (stiripentol) in the EU for juvenile myoclonic epilepsy, with Biocodex as the marketing authorization holder. The decision date was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Myoclonic Epilepsy

Drugs mentioned

• Diacomit (stiripentol)

Snippet

Status: Authorised. Therapeutic area: Myoclonic Epilepsy, Juvenile. MAH: Biocodex. Decision date: 21/08/2025